QQ客服 官方微博 反馈留言

	China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy
	Zhou, Ming; Chen, Xiaoyuan; Zhang, Hong; Xia, Lin; Tong, Xin; Zou, Limin; Hao, Ruimin; Pan, Jianhong; Zhao, Xiao; Chen, Dongmei
	2019
卷号	39期号:1页码:36
关键词	Advanced non-small cell lung cancer Anlotinib Anti-angiogenesis Epidermal growth factor receptor Activating anaplastic lymphoma kinase Adverse drug reaction National Medical Products Administration
ISSN号	2523-3548
DOI	10.1186/s40880-019-0383-7
URL标识	查看原文
收录类别	SCIE ; PUBMED
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6339942
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Zhou, Ming,Chen, Xiaoyuan,Zhang, Hong,et al. China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy[J],2019,39(1):36.
APA	Zhou, Ming.,Chen, Xiaoyuan.,Zhang, Hong.,Xia, Lin.,Tong, Xin.,...&Yang, Zhimin.(2019).China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy.,39(1),36.
MLA	Zhou, Ming,et al."China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy".39.1(2019):36.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。